clinical trial · NCT07284901
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Kailera·phase3·recruiting·n = 1,156
Obesity With DiabetesOverweight With DiabetesRibupatidePlacebo
brief summary
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
started
Jan 12, 2026
primary completion
Mar 27, 2028
completion
Apr 24, 2028
last updated
Sep 3, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol